Information Center
On June 18, 2020, Yi'an Jishi and Xinkang reached a strategic cooperation agreement.
Release time:
2019-11-20 17:16
On June 18, 2020, Beijing Xinkanghe Biological Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Xinkanghe Biological Pharmaceutical"), which focuses on the research and development of innovative drugs for the immune system, announced today a strategic cooperation with Hangzhou Yian Jishi Biopharmaceutical Co., Ltd. In this cooperation, Xinkanghe will entrust Yian Jishi to provide a full range of CMC services for one of the company's innovative antibody drugs, including cell bank construction, analytical methods, process and formulation development, GMP production, and writing of application materials.
Dr. Wu Xiaodong, Vice President of Business Operations at Xinkanghe Biological Pharmaceutical, stated: "We are very pleased to cooperate with Yian Jishi. As a company focused on developing innovative antibody drugs targeting new pathways, Xinkanghe Biological Pharmaceutical has successfully built a first-class core technology platform for antibody research and development, developing antibody new drugs with independent intellectual property rights, effectively translating scientific progress into a blessing for human life. We believe that with the help of Yian Jishi's professional capabilities and rich experience, we can efficiently advance product development and bring safe, precise, and effective new therapeutic drugs to patients."
Regarding this cooperation, Dr. Yang Xiaoming, General Manager of CDMO Business at Yian Jishi, stated: "I am very pleased to collaborate with Xinkanghe Biological Pharmaceutical, a well-known innovative drug research and development company in the field of the immune system. This cooperation highlights the recognition of Yian Jishi's comprehensive CDMO capabilities. Yian Jishi has been committed to providing high-quality, reliable, and rapid biopharmaceutical development and production services for innovative drug partners both domestically and internationally. Since 2018, we have accumulated rich project experience and look forward to helping Xinkanghe Biological Pharmaceutical accelerate the research and development process of innovative projects."
Related News
Beijing Address: A203, Zhongguancun Biomedical Park, No.5, Development Road, Haidian District, Beijing
Zhejiang Address: Floor 8, Building 7, Dongsheng Huigu, 1299 Kehai Avenue, Keqiao District, Shaoxing City, Zhejiang Province
Contact Phone:010-82176552
E-mail:hr@kanovabiopharma.com